Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eculizumab + methylprednisolone
- Development stage
- Phase 4
- Lead developer
- Alexion Pharmaceuticals
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Eculizumab + methylprednisolone is a combination therapy regimen being evaluated by the Chinese PLA General Hospital for the treatment of acute attacks in patients with neuromyelitis optica spectrum disorder (NMOSD), specifically those who are aquaporin-4 (AQP4) antibody-positive. Eculizumab is a humanized monoclonal antibody that targets the complement protein C5, inhibiting its cleavage into C5a and C5b and thereby preventing the formation of the membrane attack complex (MAC). This action mitigates the complement-mediated astrocyte damage characteristic of NMOSD. Methylprednisolone is a potent synthetic glucocorticoid used in high-dose intravenous pulses (IVMP) to provide rapid anti-inflammatory and immunosuppressive effects during an acute relapse. The combination aims to enhance clinical recovery and improve functional outcomes beyond the standard of care (corticosteroids alone) during the hyperacute phase of an attack.
- Other names
- eculizumab plus IVMPeculizumab plus intravenous methylprednisoloneeculizumab add-on therapy
02
Targets
C5Complement component C5aGR (Glucocorticoid receptor)
Beyond the preview
Go deeper on eculizumab + methylprednisolone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eculizumab + methylprednisolone.